# EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE
> **ANDA208452** · Abbreviated New Drug Application (Generic) · Sponsor: MYLAN · Approved 2025-05-20
## Drug
- **FDA Application Number:** ANDA208452
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE
- **Generic name:** EMTRICITABINE, RILPIVIRINE, TENOFOVIR DISOPROXIL FUMARATE
- **Active ingredients:** EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** MYLAN
- **Manufacturer:** Mylan Pharmaceuticals Inc.
- **First approval:** 2025-05-20
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208452)
---
*AI Analytics · CC0 1.0*